Incyte | INCY - Ebit

Stock Price
102.30
Daily Change
1.38 1.37%
Monthly
0.50%
Yearly
35.93%
Q1 Forecast
96.99

Incyte reported $431.31M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Eli Lilly USD 7.41B 391.2M Sep/2025
Exelixis USD 256.36M 42.78M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -260M 557M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Novartis USD 4.48B 343M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025